Advertisement

Advertisement

AUA 2018

AUA 2018: Finasteride Reduces Risk of Prostate Cancer and Is Safe, Long-Term Results Show

Twenty-five years after it opened for enrollment, the Prostate Cancer Prevention Trial (PCPT) has delivered a final verdict: finasteride, a common hormone-blocking drug, reduces men's risk of get...

AUA 2018: Is Prostate Cancer Screening and Risk Stratification Moving Beyond the PSA Test?

New diagnostic tests for prostate cancer, as well as new information about the impact of the U.S. Preventive Services Task Force recommendations on prostate cancer screening, were presented at the 113...

AUA 2018: Apalutamide Significantly Reduced Risk of PSA Progression in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

A post-hoc analysis from the phase III SPARTAN study that showed treatment with apalutamide (Erleada) significantly reduced the risk of prostate-specific antigen (PSA) progression in patients with non...

AUA 2018: Use of MRI for Prostate Cancer Screening and Management

Use of magnetic resonance imaging (MRI) in the diagnosis of prostate cancer is increasing and brings added value to screening and surveillance, according to new studies presented this year during the ...

AUA 2018: Panel Discusses New Research on Prostate Cancer Management Protocols and Treatments

Researchers presented new findings on a Korean Food and Drug Administration (KFDA)-approved robotic system, safety of testosterone therapy after prostate cancer, and active surveillance protocol for l...

AUA 2018: More Than 40% of Prostate Biopsies May Have Been Avoided With Use of Assay for Detection

A multicenter study that validated the clinical performance of IsoPSA—a new blood test that has proven to be more accurate in predicting overall risk of prostate cancer than standard prostate-sp...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.